US equities
|
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Enlivex Ltd. - Ordinary Shares
(NQ:
ENLV
)
1.780
-0.760 (-29.92%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Enlivex Ltd. - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
Next >
Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis
December 20, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer
November 21, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
September 11, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 07, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
November 03, 2023
Gainers Benson Hill, Inc. (NYSE: BHIL) shares jumped 48.1% to $0.3740.
Via
Benzinga
Enlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating Allocetra in Patients with COVID-19
August 02, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis
July 31, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update
June 26, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
This Biotech Is Bringing Balance To The Body – How Homeostasis Is Critical To Fighting Everything From Sepsis To Cancer
↗
June 16, 2023
Oren Hershkovitz, Ph.D., CEO of Enlivex Therapeutics Ltd. (NASDAQ: ENLV) was recently a guest on Benzinga’s All-Access.
Via
Benzinga
Enlivex to Present at the 2023 Jefferies Healthcare Conference
June 06, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy
May 31, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy
May 08, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy
April 19, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Appoints Andrew Singer to its Board of Directors
April 17, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials
April 14, 2023
Via
ACCESSWIRE
Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials
↗
April 13, 2023
This month, H.C. Wainwright & Co.
Via
Benzinga
Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors
April 12, 2023
Via
ACCESSWIRE
Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors
↗
April 11, 2023
This month, Enlivex Therapeutics Ltd.
Via
Benzinga
Why Pioneer Natural Resources Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
↗
April 10, 2023
Gainers PLx Pharma Inc. (NASDAQ: PLXP) jumped 149.6% to $0.2623 in pre-market trading after dropping over 13% on Thursday.
Via
Benzinga
Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates
April 04, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors
April 03, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers
March 20, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Receives Clearance From Spanish Agency of Medicines and Medical Devices For Treatment of Patients with Advanced Solid Malignancies in the Ongoing Allocetra Phase I/II Clinical Trial
February 23, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS
February 15, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors
January 25, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Receives Authorizations from French and Belgian Regulatory Agencies To Expand Its Phase II Sepsis Clinical Trial Into France and Belgium
January 04, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial
December 07, 2022
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced that Israel, Spain and Greece have cleared amendments to the company’s Phase II trial protocol that will allow the study to enroll more patients.
Via
TheNewswire.com
A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial
December 07, 2022
By Rachael Green, Benzinga
Via
News Direct
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
December 06, 2022
Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds.
Via
TheNewswire.com
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
December 06, 2022
By Ernest Dela Aglanu, Benzinga
Via
News Direct
< Previous
1
2
3
4
5
6
7
8
Next >
